Received Jun 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | Unknown | — |
The patient received the second dose of Rabavert 21 days after first dose; Case reference number US-BN-2025-001172 is a spontaneous case initially received from a nurse via agency (reference number: USBAV25-1660) on 09-Jul-2025 and concerns an adult female patient. The patient's medical history and concomitant medication details were not included. On 17-Jun-2025, the patient received the first dose of RabAvert along with its constituent parts prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown), at unknown dose, route or site of administration for indication Rabies vaccine. On 08-Jul-2025, 21 days after first dose, the patient received the second dose of RabAvert along with its constituent parts prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown), at unknown dose, route or site of administration (explicitly coded as 'inappropriate schedule of product administration'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to RabAvert. No further information was provided.; Reporter's Comments: This case concerns an adult female patient, who received the first dose of RabAvert for an indication of rabies vaccine. As reported, patient received second dose 21 days after the first dose, which is considered as 'inappropriate schedule of vaccine administered'. Inappropriate schedule of vaccine administered is considered as listed per company convention. At the time of the initial report, it was unknown if the patient experienced any adverse events due to RabAvert. The patient's relevant medical history and concomitant medication details were not provided. Inappropriate schedule of vaccine administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: This case concerns an adult female patient, who received the first dose of RabAvert for an indication of rabies vaccine. As reported, patient received second dose 21 days after the first dose, which is considered as 'inappropriate schedule of vaccine administered'. Inappropriate schedule of vaccine administered is considered as listed per company convention. At the time of the initial report, it was unknown if the patient experienced any adverse events due to RabAvert. The patient's relevant medical history and concomitant medication details were not provided. Inappropriate schedule of vaccine administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.